Reimbursement Review Reports


( Last Updated : May 25, 2022)

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Brilinta ticagrelor Prevention of atherothrombotic events with history of myocardial infarction Reimburse with clinical criteria and/or conditions Complete
Brilinta Ticagrelor Acute Coronary Syndromes Cancelled
Brilinta Ticagrelor Acute coronary syndromes Do not list Complete
Brineura cerliponase alfa Neuronal Ceroid Lipofuscinosis Type 2 Reimburse with clinical criteria and/or conditions Complete
Brivlera Brivaracetam Epilepsy, partial-onset seizures Reimburse with clinical criteria and/or conditions Complete
Brukinsa zanubrutinib Mantle cell lymphoma (MCL) Active
Brukinsa zanubrutinib Waldenström’s macroglobulinemia Reimburse with clinical criteria and/or conditions Complete
BuTrans Buprenorphine transdermal patch Pain, persistent (moderate intensity) Cancelled
BuTrans Buprenorphine transdermal patch Pain, moderate intensity persistent pain Do not list Complete
Byetta Exenatide Diabetes mellitus, type 2 Do not list Complete